58142-46-4

Basic information

• Product Name: 5-nitro-4-bromoisoquinoline
• Synonyms: 5-nitro-4-bromoisoquinoline
• CAS NO: 58142-46-4
• Molecular Formula: C₉H₅BrN₂O₂
• Molecular Weight: 253.055
• Mol File: 58142-46-4.mol
• Article Data: 13

Chemical Properties

• Melting Point: 172-174 °C(Solv: methanol (67-56-1))
• Boiling Point: 379.9°C at 760 mmHg
• Flash Point: 183.6°C
• Appearance: /
• Density: 1.747g/cm³
• Vapor Pressure: 1.24E-05mmHg at 25°C
• Refractive Index: 1.707
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 1.49±0.14(Predicted)
• CAS DataBase Reference: 5-nitro-4-bromoisoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 5-nitro-4-bromoisoquinoline(58142-46-4)
• EPA Substance Registry System: 5-nitro-4-bromoisoquinoline(58142-46-4)

Safety Data

• Hazardous Substances Data: 58142-46-4(Hazardous Substances Data)

Usage

General Description

5-nitro-4-bromoisoquinoline is a chemical compound with the molecular formula C9H5BrN2O2. It is a nitroso compound that consists of a core isoquinoline structure with a bromine atom at the 4-position and a nitro group at the 5-position. 5-nitro-4-bromoisoquinoline is known for its potential applications in organic synthesis and medicinal chemistry. It can be used as a building block in the synthesis of various pharmaceuticals and agrochemicals. The nitro and bromo substituents on the isoquinoline core make this compound a versatile intermediate for the preparation of diverse molecules with potentially valuable biological activities. Additionally, the presence of these functional groups also makes 5-nitro-4-bromoisoquinoline a useful reagent in a wide range of chemical reactions, including Suzuki-Miyaura cross-coupling and palladium-catalyzed C-H functionalization.

InChI:InChI=1/C9H5BrN2O2/c10-7-5-11-4-6-2-1-3-8(9(6)7)12(13)14/h1-5H

Upstream product

• 607-32-9 5-nitroisoquinoline 
• 7726-95-6 bromine 
• 1532-97-4 4-bromoisoquinoline 
• 21364-46-5 isoquinoline hydrochloride 
• 119-65-3 isoquinoline 

Downstream Products

• 16552-65-1 5-Amino-4-bromo-isoquinoline 
• 808125-51-1 5-Nitro-4-vinylisoquinoline 
• 194032-16-1 4-methyl-5-isoquinolinesulfonyl chloride 
• 194032-17-2 4-methyl-5-nitroisoquinoline 
• 1256787-17-3 4-bromo-5-chloroisoquinoline 
• 127625-94-9 4-bromo-5-isoquinolinesulphonyl chloride 
• 313484-58-1 2,3-dimethoxy-6-(5-nitroisoquinolin-4-yl)phenol 
• 313484-57-0 4-(3,4-dimethoxy-2-methoxymethoxyphenyl)-5-nitroisoquinoline 

Relevant articles and documents

KRAS G12C INHIBITORS

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

Co-administration of dopamine-receptor binding compounds

Methods for treating a patient having neurological, psychotic, and psychiatric disorders are described comprising the steps of administering to the patient an effective amount of a partial and/or full dopamine D1 receptor agonist, and administering to the patient an effective amount of a dopamine D2 receptor antagonist. Pharmaceutical compositions comprising a dopamine D1 receptor agonist and a dopamine D2 receptor antagonist are also described. The D1 dopamine receptor agonist and the D2 dopamine receptor antagonist can be administered to the patient in the same or in a different composition or compositions.

METHOD OF ADMINISTRATION OF DOPAMINE RECEPTOR AGONISTS

Methods for treating a patient having pulmonary edema are described. The methods include administering to the lung endobronchial space of the airways of the patient an effective amount of a dopamine D1 receptor agonist. Dopamine D1 receptor agonists, including hexahydrobenzophenanthridine, hexahydrothienophenanthridine, phenylbenzodiazepine, chromenoisoquinoline, naphthoisoquinoline dopamine receptor agonists, and their pharmaceutically acceptable salts, formulated as aerosols and dry powders are also described.